



\$250 Million
Follow-On Offering

svb Securities
Joint Bookrunner
February 2023

SVB Securities Serves as Joint Bookrunner for CureVac's (Nasdaq: CVAC) Upsized \$250 Million Follow-On Offering

Key Transaction Highlights

- Confidentially marketed deal that publicly launched February 6th post-close and priced February 7th post-close
- The offering followed CureVac's January 30th announcement of additional positive topline data from its Phase 1 studies of the Company's modified mRNA COVID-19 and flu vaccine constructs in other adult age groups.
- Well oversubscribed from both new and existing investors
- Base deal upsized from \$200 million to \$250 million
- Deal consisted of 27,527,028 shares of common stock being sold at a public offering price of \$9.25 per share, which represents a 1.4% discount to last sale.
- CureVac intends to use the net proceeds of this offering to fund ongoing business activities, the development of its pipeline and for other general corporate purposes.
- This is SVB Securities' first bookran offering for CureVac and 6th bookran equity offering in 2023.

For more details on this offering, visit [svb.com](#). For more details on our SVB Securities distribution, visit [svb.com](#).

THIS DEAL IS AN UNOFFICIAL DEAL. INFORMATION IS NOT BEING FURNISHED TO ANY INVESTOR BECAUSE IT IS NOT A DEAL. SVB SECURITIES LLC, THE BOOKRUNNER, IS NOT PROVIDING ANY INVESTOR INFORMATION, ONLY AND MAY NOT BE REPRODUCED FOR OR REQUIRMENT TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS DEAL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY ANY SECURITIES.

BOCA RATON
4000 South Ocean
40th Floor
Boca Raton, FL 33433

CHARLOTTE
1100 Bankers Building
Suite 1500
Charlotte, NC 28202

DALLAS, TX
40 Bankers Building
Suite 2500
Houston, TX 77010

NEW YORK
110 Bankers of the Americas
10th Floor
New York, NY 10019

SAN FRANCISCO
100 California Street
10th Floor
San Francisco, CA 94111